Company Description
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 270 |
| CEO | Benjamin Palleiko |
Contact Details
Address: 55 Cambridge Parkway, Suite 901 East Cambridge, Massachusetts 02142 United States | |
| Phone | 857 999 0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| Employer ID | 20-0915291 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Brian Piekos | Chief Financial Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Michael D. Smith Pharm.D. | Senior Vice President of Development |
| Nicole Sweeny | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2025 | 8-K | Current Report |
| Aug 21, 2025 | ARS | Filing |
| Aug 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 21, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 20, 2025 | SCHEDULE 13D/A | Filing |
| Jul 10, 2025 | 424B5 | Filing |
| Jul 10, 2025 | 10-K | Annual Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 7, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |